Cargando…

Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China

T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of lymphoma with poor clinical outcomes and no standard treatment regimen. In this study, we assessed the safety and efficacy of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) for adult T-LBL and evaluated progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yao, Rao, Jun, Li, Jiali, Wen, Qin, Wang, Sanbin, Lou, Shifeng, Yang, Tonghua, Li, Bin, Gao, Lei, Zhang, Cheng, Kong, Peiyan, Gao, Li, Wang, Maihong, Zhu, Lidan, Xiang, Xixi, Zhou, Sha, Liu, Xue, Peng, Xiangui, Zhong, Jiangfan, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776263/
https://www.ncbi.nlm.nih.gov/pubmed/31780634
http://dx.doi.org/10.3324/haematol.2019.226985
_version_ 1783630641432100864
author Liu, Yao
Rao, Jun
Li, Jiali
Wen, Qin
Wang, Sanbin
Lou, Shifeng
Yang, Tonghua
Li, Bin
Gao, Lei
Zhang, Cheng
Kong, Peiyan
Gao, Li
Wang, Maihong
Zhu, Lidan
Xiang, Xixi
Zhou, Sha
Liu, Xue
Peng, Xiangui
Zhong, Jiangfan
Zhang, Xi
author_facet Liu, Yao
Rao, Jun
Li, Jiali
Wen, Qin
Wang, Sanbin
Lou, Shifeng
Yang, Tonghua
Li, Bin
Gao, Lei
Zhang, Cheng
Kong, Peiyan
Gao, Li
Wang, Maihong
Zhu, Lidan
Xiang, Xixi
Zhou, Sha
Liu, Xue
Peng, Xiangui
Zhong, Jiangfan
Zhang, Xi
author_sort Liu, Yao
collection PubMed
description T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of lymphoma with poor clinical outcomes and no standard treatment regimen. In this study, we assessed the safety and efficacy of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) for adult T-LBL and evaluated prognostic factors affecting survival. A total of 181 newly-diagnosed adult T-LBL patients were enrolled: 89 patients were treated with chemotherapy alone, 46 were allocated to the single auto-HSCT group, 46 were treated with tandem auto-HSCT. Median follow-up time was 37 months; the 3-year progression/relapse rate of the tandem auto- HSCT group was significantly lower than that of the single auto-HSCT and chemotherapy groups (26.5% vs. 53.1% and 54.8%). The 3-year progression- free survival (PFS) and overall survival (OS) rates of the tandem auto- HSCT group (73.5% and 76.3%) were significantly higher than those of the single auto-HSCT group (46.9% and 58.3%) and the chemotherapy group (45.1% and 57.1%). In the tandem auto-HSCT group, age and disease status after the first transplant impacted OS and PFS. Multivariate analysis identified that disease status after the first transplant was the only independent prognostic factor for patients treated with tandem-HSCT. In addition, diagnostic models of the initial CD8(+)CD28(+)/CD8(+)CD28(–) T-cell ratio in predicting the disease status were found to be significant. Taken together, tandem auto- HSCT can be considered an optimal strategy for adult T-LBL patients. (Study registered at: ChiCTR-ONN-16008480).
format Online
Article
Text
id pubmed-7776263
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-77762632021-01-07 Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China Liu, Yao Rao, Jun Li, Jiali Wen, Qin Wang, Sanbin Lou, Shifeng Yang, Tonghua Li, Bin Gao, Lei Zhang, Cheng Kong, Peiyan Gao, Li Wang, Maihong Zhu, Lidan Xiang, Xixi Zhou, Sha Liu, Xue Peng, Xiangui Zhong, Jiangfan Zhang, Xi Haematologica Article T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of lymphoma with poor clinical outcomes and no standard treatment regimen. In this study, we assessed the safety and efficacy of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) for adult T-LBL and evaluated prognostic factors affecting survival. A total of 181 newly-diagnosed adult T-LBL patients were enrolled: 89 patients were treated with chemotherapy alone, 46 were allocated to the single auto-HSCT group, 46 were treated with tandem auto-HSCT. Median follow-up time was 37 months; the 3-year progression/relapse rate of the tandem auto- HSCT group was significantly lower than that of the single auto-HSCT and chemotherapy groups (26.5% vs. 53.1% and 54.8%). The 3-year progression- free survival (PFS) and overall survival (OS) rates of the tandem auto- HSCT group (73.5% and 76.3%) were significantly higher than those of the single auto-HSCT group (46.9% and 58.3%) and the chemotherapy group (45.1% and 57.1%). In the tandem auto-HSCT group, age and disease status after the first transplant impacted OS and PFS. Multivariate analysis identified that disease status after the first transplant was the only independent prognostic factor for patients treated with tandem-HSCT. In addition, diagnostic models of the initial CD8(+)CD28(+)/CD8(+)CD28(–) T-cell ratio in predicting the disease status were found to be significant. Taken together, tandem auto- HSCT can be considered an optimal strategy for adult T-LBL patients. (Study registered at: ChiCTR-ONN-16008480). Fondazione Ferrata Storti 2019-11-28 /pmc/articles/PMC7776263/ /pubmed/31780634 http://dx.doi.org/10.3324/haematol.2019.226985 Text en Copyright© 2021 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Liu, Yao
Rao, Jun
Li, Jiali
Wen, Qin
Wang, Sanbin
Lou, Shifeng
Yang, Tonghua
Li, Bin
Gao, Lei
Zhang, Cheng
Kong, Peiyan
Gao, Li
Wang, Maihong
Zhu, Lidan
Xiang, Xixi
Zhou, Sha
Liu, Xue
Peng, Xiangui
Zhong, Jiangfan
Zhang, Xi
Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title_full Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title_fullStr Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title_full_unstemmed Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title_short Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China
title_sort tandem autologous hematopoietic stem cell transplantation for treatment of adult t-cell lymphoblastic lymphoma: a multiple center prospective study in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776263/
https://www.ncbi.nlm.nih.gov/pubmed/31780634
http://dx.doi.org/10.3324/haematol.2019.226985
work_keys_str_mv AT liuyao tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT raojun tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT lijiali tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT wenqin tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT wangsanbin tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT loushifeng tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT yangtonghua tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT libin tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT gaolei tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT zhangcheng tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT kongpeiyan tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT gaoli tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT wangmaihong tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT zhulidan tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT xiangxixi tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT zhousha tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT liuxue tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT pengxiangui tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT zhongjiangfan tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina
AT zhangxi tandemautologoushematopoieticstemcelltransplantationfortreatmentofadulttcelllymphoblasticlymphomaamultiplecenterprospectivestudyinchina